arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Vera Therapeutics, Inc.

VERA Health Care Biotechnology: Pharmaceutical Preparations
$36.00
▲ +0.3% Today
as of Sep 4, 16:55 ET
Last 30 days +7.71% Jul 28 → Sep 04
$28.26 $30.56 $32.85 $35.15 $37.45 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$34.69
High
$36.41
Low
$34.69
Volume
$1M
Avg Vol
$2M
Mkt Cap
$2.1B
P/E (TTM)
—
Beta
—
52w High
$56.05
52w Low
$22.72
Div Yield
—
Shares Out
—

Recent Press Releases & News last 60 days · 13 items

Sep 4 · 20:05 PR GlobeNewswire
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 1 · 11:30 PR GlobeNewswire
Vera Therapeutics to Participate at Upcoming Investor Conferences
Aug 11 · 11:17 MT Newswires
Wedbush Adjusts Price Target on Vera Therapeutics to $34 From $43, Maintains Neutral Rating
▸ Show all 13 press releases & news Free account →

Overview

52-week range
$23
$56
40% of range
Avg surprise (last 3)
-29.5%
Avg reaction (last 2)
-7.9%
0% positive
Latest IV / EM
132%
EM ±20.6% · $35 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-1.69$-1.38$-1.07$-0.76$-0.45 Actual $-0.80Actual $-0.46Actual $-0.45Actual $-0.56Actual $-0.62Actual $-0.85Actual $-0.81Est $-0.75Actual $-1.20Est $-0.82Actual $-1.26Actual $-1.69Est $-1.26Actual $-1.52 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-121M$-103M$-85M$-67M$-49M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-1.52 — — — — financials
Thu May 7, 2026Mar/2026 $-1.69 $-1.26 -34.1% -108.6% -2.0% earnings
Tue Sep 30, 2025Sep 2025 $-1.26 — — — — financials
Tue Aug 5, 2025Jun/2025 $-1.20 $-0.82 -46.3% — — earnings
Tue May 6, 2025Mar/2025 $-0.81 $-0.75 -8.0% — -13.8% earnings
Mon Sep 30, 2024Sep 2024 $-0.85 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.62 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.56 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.45 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.46 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.80 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-112M$-125M—$-84M$-80M$-57M—$-50M
Net income$-109M$-121M—$-80M$-77M$-52M—$-47M
EPS (diluted)$-1.52$-1.69—$-1.26$-1.20$-0.81—$-0.85

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$49M$114M$355M$58M$49M$55M$93M$27M
Inventory————————
Total current assets$527M$616M$729M$511M$571M$606M$651M$364M
Total assets$533M$622M$735M$518M$579M$610M$656M$369M
Long-term debt$75M$75M$75M$75M$74M$51M$51M$50M
Total liabilities$125M$122M$130M$119M$110M$75M$79M$80M
Total equity$408M$500M$605M$399M$468M$535M$577M$289M

Implied volatility — last 90 days

68%113%157%202%246% Jun 07 — IV 119% · EM ±16.5%Jun 08 — IV 110% · EM ±14.6%Jun 09 — IV 111% · EM ±13.9%Jun 10 — IV 123% · EM ±14.5%Jun 11 — IV 95% · EM ±10.6%Jun 12 — IV 70% · EM ±7.2%Jun 15 — IV 88% · EM ±6.4%Jun 16 — IV 224% · EM ±13.2%Jun 17 — IV 159% · EM ±6.6%Jun 19 — IV 102% · EM ±22.5%Jun 22 — IV 115% · EM ±24.1%Jun 23 — IV 111% · EM ±22.8%Jun 24 — IV 109% · EM ±21.8%Jun 25 — IV 118% · EM ±23.2%Jun 26 — IV 145% · EM ±27.8%Jun 29 — IV 166% · EM ±29.4%Jun 30 — IV 173% · EM ±29.8%Jul 01 — IV 166% · EM ±27.6%Jul 02 — IV 155% · EM ±25.1%Jul 03 — IV 160% · EM ±25.0%Jul 06 — IV 152% · EM ±21.1%Jul 07 — IV 90% · EM ±11.9%Jul 08 — IV 72% · EM ±9.0%Jul 09 — IV 69% · EM ±8.2%Jul 10 — IV 77% · EM ±8.5%Jul 13 — IV 94% · EM ±7.9%Jul 14 — IV 100% · EM ±7.3%Jul 15 — IV 107% · EM ±6.3%Jul 16 — IV 140% · EM ±5.9%Jul 20 — IV 75% · EM ±17.7%Jul 21 — IV 69% · EM ±16.1%Jul 22 — IV 69% · EM ±15.7%Jul 23 — IV 71% · EM ±16.0%Jul 24 — IV 82% · EM ±18.1%Jul 27 — IV 76% · EM ±15.8%Jul 28 — IV 70% · EM ±14.2%Jul 29 — IV 99% · EM ±19.8%Jul 30 — IV 75% · EM ±14.6%Jul 31 — IV 75% · EM ±14.4%Aug 03 — IV 123% · EM ±21.7%Aug 04 — IV 128% · EM ±22.0%Aug 05 — IV 107% · EM ±18.0%Aug 06 — IV 121% · EM ±19.6%Aug 07 — IV 77% · EM ±12.1%Aug 10 — IV 109% · EM ±15.0%Aug 11 — IV 97% · EM ±12.8%Aug 12 — IV 76% · EM ±9.5%Aug 13 — IV 75% · EM ±8.9%Aug 14 — IV 78% · EM ±8.6%Aug 17 — IV 149% · EM ±12.5%Aug 18 — IV 158% · EM ±11.5%Aug 19 — IV 247% · EM ±14.6%Aug 20 — IV 221% · EM ±9.2%Aug 24 — IV 71% · EM ±14.9%Aug 25 — IV 81% · EM ±16.6%Aug 26 — IV 94% · EM ±18.8%Aug 27 — IV 117% · EM ±22.9%Aug 28 — IV 99% · EM ±18.9%Aug 31 — IV 103% · EM ±18.2%Sep 01 — IV 106% · EM ±18.3%Sep 02 — IV 101% · EM ±16.8%Sep 03 — IV 106% · EM ±17.2%Sep 04 — IV 132% · EM ±20.6%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in